title: Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides.
abstract: BACKGROUND
  The renal 11beta-hydroxysteroid dehydrogenase type 2 (11beta HSD2) enzyme inactivates 11-hydroxy steroids in the kidney, thereby protecting the nonselective mineralocorticoid (MR) receptor from occupation by glucocorticoids. Loss-of-function mutations in the gene encoding 11beta HSD2 (HSD11B2) result in overstimulation of the MR and cause salt-sensitive hypertension.
  
  
  METHODS
  We have investigated the role of HSD11B2 in hypertension in 377 genetically homogeneous essential hypertensives from North Sardinia.
  
  
  RESULTS
  Thirty of these patients displayed increased urinary cortisol metabolite ratios (greater than or equal to 2) (tetrahydrocortisol [THF]+allotetrahydrocortisol [aTHF]/tetrahydrocortisone [THE]) reflecting a mild reduction in 11beta HSD2 activity. No mutations in HSD11B2 were detected in these patients. All 377 patients were genotyped for a CA repeat microsatellite in intron 1 of HSD11B2 and a G534A polymorphism in exon 3 of HSD11B2. CA repeat length was associated with the (THF+aTHF)/THE ratio, which in turn was significantly related to PRA levels. No associations were found between the G354A polymorphism and the other parameters. There were no differences in blood pressure (BP) levels between HSD11B2 genotypes, but in a subgroup of 91 patients that underwent diuretic therapy, CA repeat length was strongly associated with the BP response to hydrochlorothiazide.
  
  
  CONCLUSIONS
  This study highlights the role of this HSD11B2 polymorphism in sodium handling and is consistent with a role in the BP response to thiazide diuretics.
authors.affiliation: Hypertension Unit, Department of Medicine and Experimental Oncology, University of Torino, Torino, Italy.
authors.forename: Tracy A
authors.initials: TA
authors.lastname: Williams
authors.forename: Paolo
authors.initials: P
authors.lastname: Mulatero
authors.forename: Fabiana
authors.initials: F
authors.lastname: Filigheddu
authors.forename: Chiara
authors.initials: C
authors.lastname: Troffa
authors.forename: Alberto
authors.initials: A
authors.lastname: Milan
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Argiolas
authors.forename: Paolo Pinna
authors.initials: PP
authors.lastname: Parpaglia
authors.forename: Franco
authors.initials: F
authors.lastname: Veglio
authors.forename: Nicola
authors.initials: N
authors.lastname: Glorioso
mesh_terms: D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2 / Q000235:genetics*; D000328:Adult; D001581:Benzothiadiazines; D004232:Diuretics; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D007438:Introns; D018895:Microsatellite Repeats; D008875:Middle Aged; D010641:Phenotype; D011110:Polymorphism, Genetic; D012083:Renin / Q000097:blood; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*; D013760:Tetrahydrocortisol / Q000652:urine
chemical_list: D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D013760:Tetrahydrocortisol; D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2; C468387:HSD11B2 protein, human; D012083:Renin